Identifying biomarkers that may affect diabetes comorbidity

This project is funded by:

  • DfE CAST award in collaboration with Novo Nordisk Research Centre Oxford

Summary

It is estimated that 415 million people worldwide suffer from diabetes which will rise to 642 million by 20401.  Ninety percent of cases are type 2 diabetes (T2D).  Treatment of secondary complications/comorbidities accounts for ~75% of the costs associated with T2D in the NHS2.  T2D is associated with hypertension (76%), arthritis (55%), coronary disease (28%), neuropathy (21%) and renal disease (18%)3; 47% of patients suffer 3 or more comorbidities.

Comorbid patients are routinely excluded from clinical trials, limiting our understanding of how treatments affect comorbidities4.  Comorbid patients commonly receive separate, fragmented treatment for each morbidity, with implications for cost and quality of care5.  It is not well understood (i) whether the association between comorbidities is driven by pathophysiological or lifestyle factors and (ii) whether one morbidity is causative of another or whether they share common causes.

There is a vast potential to grow our understanding of comorbidity and develop diagnostics, prognostics and interventions that can improve the quality of care for comorbid patients.  Here, we will focus on the pathophysiology of comorbidity and establish the relationship between T2D and its key comorbidities.

Aim 1 – Profile comorbidity in populations representative of the UK.

* Extract clinical and ‘omics data from UK Biobank (which does not cover Northern Ireland) and Ulster Genome Project, a large patient cohort study conducted by the Northern Ireland Centre for Stratified Medicine

* Prepare multidimensional analysis of comorbidity in T2D and identify significant morbidity combinations.

Aim 2 – Model the pathway biology of the key comorbidities.

* Use published literature, online databases and systems biology tools to map out the known molecular pathways that connect comorbidities.

* Develop and evaluate dynamic systems biology models of relevant molecular pathways.

Aim 3 – Identify genes/proteins/pathways associated with comorbidity development and targets contained therein.

* Undertake a gene set analysis of genome/proteome-wide association studies to determine SNPs/proteins/pathways statistically associated with development of significant morbidity combinations.

* Identify how loss-of-function/gain-of-function SNPs in genes or elevated/reduced protein/pathway activity drive comorbidity development.

* Identify SNPs in genes or binding sites in proteins that can be targeted to counter comorbidity development, therapeutically moderating comorbidity development.

The output of the project will be sets of predictive biomarkers of comorbidity and hypotheses of how these may be targeted therapeutically.  Biomarkers may be patentable and Ulster University (UU) has experience of securing Biomarker Intellectual Property.

The student will be placed at Ulster University (UU, 50% of time) and at Novo Nordisk (NN, 50%), including time at NN Research Centre Oxford (NNRCO) and NN’s headquarters near Copenhagen.  They will experience research in academic and industrial environments, with UU supporting data exploration and systems analysis/modelling (aims 1 and 2) and NNRCO supporting the analysis driving therapeutic target identification (aim 3). Comorbidity is an embryonic biomedical field and all aspects of the project will be novel and can lead to scientific publication.

[1] Ogurtsova K, et al. Diab Res Clin Pract (2017) 128, 40-50.

[2] Hex N, et al. Diabetic Med (2012) 29(7) 855-862.

[3] Kerr EA, et al. J General Internal Med (2007) 22(12), 1635-40.

[4] Gibson DS, et al. Exp Rev Precision Med Drug Dev (2017) 2(3) 147-156.

[5] Wallace E, et al. BMJ (2015) 305:H176.

Desirable Criteria

If the University receives a large number of applicants for the project, the following desirable criteria may be applied to shortlist applicants for interview.

  • Demonstrable programming skills and mathematical ability.
  • Familiarity with biomedical science is desirable, but not essential.
  • Completion of Masters at a level equivalent to commendation or distinction at Ulster is desirable, but not essential.
  • A background in biomedical science, stratified/personalised medicine, bioinformatics, biomedical engineering, computer science, mathematics, physics or another quantitative science.

Essential criteria

Applicants should hold, or expect to obtain, a First or Upper Second Class Honours Degree in a subject relevant to the proposed area of study.

We may also consider applications from those who hold equivalent qualifications, for example, a Lower Second Class Honours Degree plus a Master’s Degree with Distinction.

In exceptional circumstances, the University may consider a portfolio of evidence from applicants who have appropriate professional experience which is equivalent to the learning outcomes of an Honours degree in lieu of academic qualifications.

  • Sound understanding of subject area as evidenced by a comprehensive research proposal

Funding and eligibility

This project is funded by:

  • DfE CAST award in collaboration with Novo Nordisk Research Centre Oxford
  • The scholarship will cover tuition fees at the Home rate and a maintenance allowance of £ 16,009 per annum for three years. EU applicants will only be eligible for the fee’s component of the studentship (no maintenance award is provided). For Non-EU nationals the candidate must be "settled" in the UK. This scholarship also comes with £900 per annum for three years as a research training support grant (RTSG) allocation to help support the PhD researcher.

    The Doctoral College at Ulster University

    Key dates

    Submission deadline
    Friday 7 February 2020
    12:00AM

    Interview Date
    9 to 20 March 2020

    Preferred student start date
    Mid September 2020

    Applying

    Apply Online  

    Contact supervisor

    Dr Steven Watterson

    Other supervisors

    Back to Top